NeurAxis is currently navigating a critical commercial expansion phase for its IB-Stim device, evidenced by a 79.5% year-over-year revenue growth rate in 2026Q1. While the company maintains high gross margins of 86.4%, the lack of operational leverage, reflect...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.19+40.6% vs -$0.32 | $2M-3.6% vs $2M |
Q2 2026 May 12, 2026 | -$0.18+5.3% vs -$0.19 | $2M+10.9% vs $1M |
Q2 2026 Mar 19, 2026 | -$0.17+20.9% vs -$0.21 | $968,000+13.9% vs $850,000 |
Q4 2025 Nov 10, 2025 | -$0.24-20.0% vs -$0.20 | $811,414-18.9% vs $1M |
MariMed (OTCMKTS:MRMD - Get Free Report) and NeurAxis (NASDAQ: NRXS - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations. Analyst Ratings This is a breakdown of recent ratings
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”).
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.
NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.
Benchmark NRXS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for NeurAxis, Inc. (NRXS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.46 | $93.08M | -7.85 | 32.89% | -218.55% | -285.36% | — | |
| $77.16 | $4.24B | -17.34 | 10.74% | 12.82% | 15.41% | — | |
| $27.57 | $228.28M | 32.06 | 16.97% | 15.32% | 23.38% | — | |
| $2.88 | $200.41M | -4.88 | 99.17% | -19.62% | -126.4% | — | |
| $89.30 | $114.65B | 23.94 | 8.43% | 13.93% | 10.51% | — | |
| $103.53 | $180.32B | 27.83 | 5.67% | 13.91% | 12.09% | — |
NeurAxis, Inc. (NRXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
NeurAxis, Inc. (NRXS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 10, 2026·SEC
Jun 12, 2026·SEC
Apr 22, 2026·SEC
Get notified when NRXS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NeurAxis, Inc. (NRXS) stock FAQ — growth, dividends, profitability & financials explained
NeurAxis, Inc. (NRXS) reported $5.3M in revenue for fiscal year 2025. This represents a 175% increase from $1.9M in 2020.
NeurAxis, Inc. (NRXS) grew revenue by 32.9% over the past year. This is strong growth.
NeurAxis, Inc. (NRXS) reported a net loss of $7.9M for fiscal year 2025.
NeurAxis, Inc. (NRXS) has a return on equity (ROE) of -285.4%. Negative ROE indicates the company is unprofitable.
NeurAxis, Inc. (NRXS) had negative free cash flow of $5.6M in fiscal year 2025, likely due to heavy capital investments.
